Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5155MR)

This product GTTS-WQ5155MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets Canlupfam IL31 gene. The antibody can be applied in Canine atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Caninized
RefSeq NM_001165914.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100302725
UniProt ID Q9N0W9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ5155MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14167MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ11516MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ7154MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA FG-3019
GTTS-WQ9984MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KD-247
GTTS-WQ13205MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ10228MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ1401MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABT-981
GTTS-WQ1636MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-910
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW